Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Depreciation & Amortization (CF) (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $582000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 23.42% to $582000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.6 million, a 37.77% increase, with the full-year FY2024 number at $2.3 million, up 91.86% from a year prior.
  • Depreciation & Amortization (CF) was $582000.0 for Q3 2025 at Inhibrx Biosciences, down from $662000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $760000.0 in Q3 2024 to a low of $298000.0 in Q4 2023.
  • A 3-year average of $533888.9 and a median of $582000.0 in 2025 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): surged 150.0% in 2024, then fell 23.42% in 2025.
  • Inhibrx Biosciences' Depreciation & Amortization (CF) stood at $298000.0 in 2023, then skyrocketed by 131.21% to $689000.0 in 2024, then dropped by 15.53% to $582000.0 in 2025.
  • Per Business Quant, the three most recent readings for INBX's Depreciation & Amortization (CF) are $582000.0 (Q3 2025), $662000.0 (Q2 2025), and $675000.0 (Q1 2025).